Solid Biosciences (SLDB) Change in Account Payables (2017 - 2026)
Solid Biosciences (SLDB) reported Change in Account Payables of $2.3 million for Q1 2026, up 403.47% on a YoY basis from $461000.0 in Q1 2025, and up 144.15% sequentially from -$5.3 million in Q4 2025.
Solid Biosciences (SLDB) Change in Account Payables (2017 - 2026) Analysis & Trends
Solid Biosciences (SLDB) has 10 years of Change in Account Payables data on file, last reported at $2.3 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 403.47% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $767000.0 (down 76.49% YoY), and the FY2025 full-year result was -$1.1 million, down 149.57% from the prior year.
- Change in Account Payables advanced to $2.3 million in Q1 2026, from -$5.3 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $3.7 million in Q3 2025 to a low of -$5.9 million in Q4 2022.
- A 5-year average of -$151588.2 and a median of $287000.0 in 2022 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables sank 1136.14% in 2022 and soared 3766.2% in 2023, its largest moves.
- Tracing SLDB's Change in Account Payables over 5 years: stood at -$5.9 million in 2022, then jumped by 102.27% to $134000.0 in 2023, then soared by 508.21% to $815000.0 in 2024, then sank by 745.03% to -$5.3 million in 2025, then soared by 144.15% to $2.3 million in 2026.
- Business Quant data shows SLDB's Change in Account Payables at $2.3 million in Q1 2026, -$5.3 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Solid Biosciences | 529.40 Mn | 529.40 Mn | - | 2.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.32 Mn |
| Mar 31, 2026 | 2.32 Mn |
| Dec 31, 2025 | -5.26 Mn |
| Dec 31, 2025 | -5.26 Mn |
| Sep 30, 2025 | 3.70 Mn |
| Sep 30, 2025 | 3.70 Mn |
| Jun 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | 461,000.00 |
| Mar 31, 2025 | 461,000.00 |
| Dec 31, 2024 | 815,000.00 |
| Dec 31, 2024 | 815,000.00 |
| Sep 30, 2024 | 918,000.00 |
| Sep 30, 2024 | 918,000.00 |
| Jun 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | -596,000.00 |
| Mar 31, 2024 | -596,000.00 |
| Dec 31, 2023 | 134,000.00 |
| Dec 31, 2023 | 134,000.00 |